RARE
Price:
$55.24
Market Cap:
$5.09B
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hyper...[Read more]
Industry
Biotechnology
IPO Date
2014-01-31
Stock Exchange
NASDAQ
Ticker
RARE
According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.66. This represents a change of 25.39% compared to the average of -6.11 of the last 4 quarters.
The mean historical PE Ratio of Ultragenyx Pharmaceutical Inc. over the last ten years is -15.23. The current -7.66 PE Ratio has changed 4.93% with respect to the historical average. Over the past ten years (40 quarters), RARE's PE Ratio was at its highest in in the June 2020 quarter at 46.34. The PE Ratio was at its lowest in in the December 2020 quarter at -93.20.
Average
-15.23
Median
-11.14
Minimum
-45.15
Maximum
-4.58
Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 652.43%
Maximum Annual PE Ratio = -4.58
Minimum Annual Increase = -72.19%
Minimum Annual PE Ratio = -45.15
Year | PE Ratio | Change |
---|---|---|
2023 | -5.80 | 26.61% |
2022 | -4.58 | -63.53% |
2021 | -12.56 | -72.19% |
2020 | -45.15 | 652.43% |
2019 | -6.00 | -45.21% |
2018 | -10.95 | 68.06% |
2017 | -6.52 | -42.43% |
2016 | -11.32 | -60.05% |
2015 | -28.34 | 34.30% |
2014 | -21.10 | -39.74% |
The current PE Ratio of Ultragenyx Pharmaceutical Inc. (RARE) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-7.64
5-year avg
-14.82
10-year avg
-15.23
Ultragenyx Pharmaceutical Inc.’s PE Ratio is less than X4 Pharmaceuticals, Inc. (7.41), less than Terns Pharmaceuticals, Inc. (-6.06), less than Day One Biopharmaceuticals, Inc. (-7.39), less than PDS Biotechnology Corporation (-2.64), less than Inozyme Pharma, Inc. (-3.48), less than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-0.97), greater than Apellis Pharmaceuticals, Inc. (-15.28), greater than Crinetics Pharmaceuticals, Inc. (-15.40), less than Arvinas, Inc. (-5.42), greater than Revolution Medicines, Inc. (-13.31), greater than Kura Oncology, Inc. (-9.19), less than Acumen Pharmaceuticals, Inc. (-2.06), less than Incyte Corporation (137.37), greater than Alnylam Pharmaceuticals, Inc. (-428.77), less than United Therapeutics Corporation (14.35),
Company | PE Ratio | Market cap |
---|---|---|
7.41 | $109.78M | |
-6.06 | $549.60M | |
-7.39 | $1.25B | |
-2.64 | $107.88M | |
-3.48 | $312.42M | |
-5.32 | $4.12B | |
-0.97 | $161.36M | |
-15.28 | $5.00B | |
-15.40 | $4.03B | |
-5.42 | $1.68B | |
-13.31 | $6.99B | |
-9.19 | $1.48B | |
-2.06 | $133.38M | |
137.37 | $11.80B | |
-428.77 | $31.68B | |
14.35 | $15.38B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Ultragenyx Pharmaceutical Inc.'s PE Ratio?
How is the PE Ratio calculated for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the highest PE Ratio for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 3-year average PE Ratio for Ultragenyx Pharmaceutical Inc. (RARE)?
What is the 5-year average PE Ratio for Ultragenyx Pharmaceutical Inc. (RARE)?
How does the current PE Ratio for Ultragenyx Pharmaceutical Inc. (RARE) compare to its historical average?